[Melbourne], [7 May 2026] — Lyrebird Health, the AI clinical documentation platform, today announced the appointment of Dr. Ray Boyapati as Chief Clinical Officer. The appointment signals a defining moment for Lyrebird: a deliberate, company-wide commitment to building AI that clinicians, health systems, and patients can trust completely.

The first wave of AI clinical documentation proved the technology could work. This moment demands something harder: proving it can be trusted. By patients, health systems, teaching hospitals, and the clinical leaders who set the ceiling for what excellent care looks like.

The institutions that matter most, the high-intensity environments where AI's impact will be greatest and the stakes are highest won't deploy without clinical governance infrastructure they can audit and defend. Emergency departments, ICUs, major health systems: these don't make decisions based on demos. They make them based on who is responsible when something goes wrong, and what systems exist to catch it before it does.

The companies that earn the trust of these environments will define the category. Those that don't will be confined to the edges of it. Appointing a Chief Clinical Officer, someone embedded in active clinical practice, with the credibility to engage health system leadership as a peer is how Lyrebird earns the right to operate at that level.

About Dr. Ray Boyapati

There are clinicians who understand medicine, and there are clinicians who understand how to build things inside it. Dr. Ray Boyapati is both, and the combination is rare.

As a consultant gastroenterologist at Monash Health specialising in inflammatory bowel disease, Adjunct Senior Lecturer at Monash University, and holder of a doctorate from the University of Edinburgh, Dr. Boyapati brings clinical depth that is genuinely uncommon at the executive level. His peer-reviewed research has been cited over 1,900 times. A body of work that reflects both the rigour and the clinical stakes he brings to every problem he works on. He also serves in a leadership capacity at the Gastroenterological Society of Australia (GESA), where he has been a consistent advocate for patients and the profession..

Beyond his clinical practice, Dr. Boyapati founded MedEntry, which has guided tens of thousands of students through medical school entry across Australia, New Zealand, the UK, and Ireland. Building at scale inside a credentialed, trust-dependent sector - understanding what it takes for a system to earn the confidence of a profession is exactly the experience Lyrebird needs at this stage.

What distinguishes this appointment is that Dr. Boyapati's clinical life doesn't pause when he steps into this role. He will continue to practice, to teach the next generation of clinicians at Monash University, and to advocate for patients and clinicians through GESA - stress-testing Lyrebird's AI against the reality of active clinical practice, every day. He joins Lyrebird with a mandate to embed clinical rigour into the DNA of the product, not as a feature, but as a foundation.

As Lyrebird expands its clinical operations across Australia and the UK, the company is actively growing its clinical team to meet the demands of its most complex healthcare environments.

Leadership Perspective

"We started Lyrebird with the belief that technology could solve one of the most painful problems in healthcare - the administrative burden that weighs on clinicians every day. The opportunity to make real change is enormous. But so is the responsibility to do it right, because what we build has real consequences for the clinicians using it and the patients they care for.

As we build this, grounding every decision in clinical reality is the standard and Ray's continued practice makes that possible. His perspective ensures our work is tested against the pressures providers actually face, building something clinicians can genuinely rely on to sustain the care that brought them to medicine in the first place.”

— Kai Van Lieshout, Founder & CEO, Lyrebird Health

"As a practising clinician, I've seen firsthand that healthcare technology succeeds or fails in the details of real clinical work. In busy clinics, with complex patients, imperfect information, and decisions that carry real consequences. AI cannot be built for that environment from a distance. 

What drew me to Lyrebird was that the team already understood this. Clinical trust is not treated as a marketing claim here, it shapes how decisions get made. And at the scale Lyrebird is now operating, with real clinicians, real patients, and real consequences, formalising that clinical leadership felt not just right, but necessary. 

The best technology will not be imposed on healthcare. It will be shaped with the people who have to live with its consequences."

— Dr. Ray Boyapati, Chief Clinical Officer, Lyrebird

A New Standard for Clinical AI Safety

Dr. Boyapati’s appointment formalises Lyrebird’s clinical safety framework, which includes:

• A public commitment to publishing Lyrebird’s clinical safety standards, holding the company accountable to the industry, not just its customers.
• Clinical oversight of all AI model development and output validation, with physician-led review processes embedded in the product lifecycle.
• A Clinical Advisory Council to provide independent clinical judgement from experienced clinicians into important product and safety decisions.
• Transparent error reporting and continuous feedback loops with frontline healthcare providers.
• Rigorous alignment with clinical governance standards, interoperability requirements, and emerging AI safety regulations across key markets.

About Lyrebird Health

Lyrebird is an AI clinical documentation platform purpose-built for healthcare providers. By automating the capture and structuring of clinical notes, Lyrebird reduces administrative burden, improves documentation accuracy, helps clinicians spend more time on patient care and elevates the clinical standard. Trusted by leading healthcare organisations and clinicians across Australia, the UK, and the UAE, Lyrebird is backed by leading investors committed to transforming the future of healthcare delivery.

Learn more at https://www.lyrebirdhealth.com

Media Contact

Yen Hoang

Marketing & Communications, Lyrebird Health

yen@lyrebirdhealth.com